← Leaderboards
Gloria Huei-Ting Su
Johns Hopkins University
$8,620,087
Attributed
$8,620,087
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $956.1K · FY2005–21$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$8,620,087 · 6
By mechanism
R01$7,264,137 · 3
K01$706,522 · 1
R21$398,475 · 1
R56$250,953 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Irina Petrache$14,015,590
- Enid R Neptune$11,248,461
- Se-Jin Lee$17,681,857
- Anirban Maitra$50,247,714
- Wayne Mitzner$20,452,046
Others in their field
Top investigators on “Pancreas”
- David Heimbrook · Leidos Biomedical Research, Inc.$73,277,592
- Jeffrey P Krischer · University Of South Florida$62,791,489
- Klaus H. Kaestner · University Of Pennsylvania$51,057,263
- Anirban Maitra · Johns Hopkins University$43,666,915
- Charles A Coltman · Southwest Oncology Group$36,817,493
- Ali Naji · University Of Pennsylvania$30,540,599
Research focus
PancreasPancreatic Ductal AdenocarcinomaTumor Suppressor GenesPathway InteractionsMalignant NeoplasmsTumor ProgressionLeadPancreatic TumorigenesisMalignant Neoplasm Of PancreasTumorTumorigenesisIn VivoLesionGenesPancreatic NeoplasmPancreatic Intraepithelial NeoplasiaOncogenicMouse ModelDesignReportingNeoplasm MetastasisOncogenesIn VitroPremalignant
Grant awards (28)
The Development And Progression Of IPMN To PDA In The Context Of Inactivated Activin Signaling$480,016
R01 · FY2021 · CA · contact PI
The Development And Progression Of IPMN To PDA In The Context Of Inactivated Activin Signaling$484,816
R01 · FY2020 · CA · contact PI
The role of wild-type KRAS in the context of tumor profession and metastasis$478,277
R01 · FY2019 · CA · contact PI
The Development And Progression Of IPMN To PDA In The Context Of Inactivated Activin Signaling$477,871
R01 · FY2019 · CA · contact PI
The Development And Progression Of IPMN To PDA In The Context Of Inactivated Activin Signaling$489,796
R01 · FY2018 · CA · contact PI
The role of wild-type KRAS in the context of tumor profession and metastasis$450,563
R01 · FY2018 · CA · contact PI
The role of wild-type KRAS in the context of tumor profession and metastasis$462,118
R01 · FY2017 · CA · contact PI
The Development And Progression Of IPMN To PDA In The Context Of Inactivated Activin Signaling$454,195
R01 · FY2017 · CA · contact PI
The role of wild-type KRAS in the context of tumor profession and metastasis$436,453
R01 · FY2016 · CA · contact PI
The role of wild-type KRAS in the context of tumor profession and metastasis$409,343
R01 · FY2015 · CA · contact PI
Mouse Model for Human Pancreatic Ductal Adenocarcinoma$250,358
R01 · FY2015 · CA · contact PI
Mouse Model for Human Pancreatic Ductal Adenocarcinoma$306,847
R01 · FY2014 · CA · contact PI
Mouse Model for Human Pancreatic Ductal Adenocarcinoma$235,337
R01 · FY2013 · CA · contact PI
Mouse Model for Human Pancreatic Ductal Adenocarcinoma$311,158
R01 · FY2012 · CA · contact PI
Mouse Model for Human Pancreatic Ductal Adenocarcinoma$250,358
R01 · FY2011 · CA · contact PI
Mouse Model for Human Pancreatic Ductal Adenocarcinoma$250,953
R56 · FY2009 · CA · contact PI
The tumor-suppressive role of ALK4/ACVR1B in pancreatic tumorigenesis$181,125
R21 · FY2009 · CA · contact PI
Mouse Model for Human Pancreatic Ductal Adenocarcinoma$250,358
R01 · FY2008 · CA · contact PI
The tumor-suppressive role of ALK4/ACVR1B in pancreatic tumorigenesis$217,350
R21 · FY2008 · CA · contact PI
Mouse Model for Human Pancreatic Ductal Adenocarcinoma$250,358
R01 · FY2007 · CA · contact PI
Mouse Model for Human Pancreatic Ductal Adenocarcinoma$257,835
R01 · FY2006 · CA · contact PI
DPC4 function in human pancreatic cancer$155,450
K01 · FY2006 · CA · contact PI
Mouse Model for Human Pancreatic Ductal Adenocarcinoma$264,040
R01 · FY2005 · CA
DPC4 function in human pancreatic cancer$132,033
K01 · FY2005 · CA
Mouse Model for Human Pancreatic Ductal Adenocarcinoma$264,040
R01 · FY2004 · CA
DPC4 function in human pancreatic cancer$149,623
K01 · FY2004 · CA
DPC4 function in human pancreatic cancer$146,837
K01 · FY2003 · CA
DPC4 function in human pancreatic cancer$122,579
K01 · FY2002 · CA